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Background. It is currently impossible to reliably predict
which diabetic patients will develop nephropathy and progress
to kidney failure. Microalbuminuria, often regarded as a pre-
dictor of overt diabetic renal disease is, in fact, an indicator of
established glomerular damage. We have shown that glomeru-
lar expression of the prosclerotic cytokine CCN2 (CTGF) is
greatly up-regulated early in experimental and in human diabe-
tes and mesangial cell exposure to CCN2 increases its produc-
tion of extracellular matrix (ECM) molecules responsible for
glomerulosclerosis. As an early marker, we therefore investi-
gated the presence of CCN2 in urine and the relationship to
diabetes and/or renal disease in an experimental model of
diabetes and in a limited patient population.
Methods. Urine samples from (1) healthy rats, (2) rats made
diabetic by streptozotocin (STZ), (3) healthy human volun-
teers, (4) diabetic patients with renal disease, and (5) diabetic
patients without renal disease were examined by Western blot-
ting and/or enzyme-linked immunosorbent assay (ELISA) for
qualitative and quantitative analysis of the of CCN2.
Results. Low levels of urinary CCN2 were present in healthy,
control rats, but were increased approximately sevenfold over-
all in STZ-diabetic animals. CCN2 levels were the highest at
week 3 of diabetes, then decreased with time, but remained
significantly elevated over controls even after 32 weeks. Consis-
tently low levels of urinary CCN2 were also detected in healthy
volunteers (mean value, 7.1 CCN2/mg creatinine). However,
levels were elevated approximately sixfold in the majority of
diabetic patients with nephropathy. A small number of the
diabetic patients not yet exhibiting evidence of renal involve-
ment demonstrated CCN2 urinary levels that were ninefold
greater than controls. The remaining normoalbuminuric dia-
betic patients demonstrated CCN2 levels indistinguishable from
those of healthy volunteers. Analysis by Western blotting con-
firmed the identity of the urinary CCN2. A molecular species
equivalent to full-length CCN2 (37/39 kD doublet) was present
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in healthy controls. In contrast, the nephropathic group demon-
strated multiple CCN2 bands.
Conclusion. These findings support our hypothesis that
CCN2 is up-regulated early in the evolution of glomerulosclero-
sis, including that of diabetes. We contend that urinary CCN2
may both stage nephropathy and predict those patients who
are destined for progressive glomerulosclerosis and end-stage
renal disease (ESRD). Cross-sectional and prospective studies
of larger, well-defined diabetic patients groups will be required
to prove this hypothesis, and are ongoing.
Kidney failure resulting from progressive glomerulo-
sclerosis is the leading cause of morbidity and mortality
among patients with type 1 and type 2 diabetes [1, 2].
Current therapy with angiotensin-converting enzyme
(ACE) inhibitors or angiotensin II receptor blockers, the
drug classes of choice, effectively slow the progression
of disease [3–6]. Nevertheless, such treatments are not
justified in all newly diagnosed diabetic patients because
only approximately 30% to 40% of these develop pro-
gressive renal disease, and the long-term side effects
of these drugs are uncertain [6, 7]. Currently, diabetic
patients are monitored for microalbuminuria. Persistent
microalbuminuria is a marker of widespread vascular
damage [8] and it has been regarded as an indicator of
incipient nephropathy in type 1 and type 2 diabetes [9, 10].
However, the actual level of microalbuminuria may not
necessarily predict the development of overt, clinical
nephropathy, particularly among patients with a long
duration of diabetes [9]. In addition, by the time micro-
albuminuria is detected, structural renal lesions are often
already present [10–12]. Therefore, there is a great need
for an early marker, or predictor, of nephropathy among
diabetic patients. Patients with an earlier diagnosis would
then likely benefit from an earlier initiation of therapy.
Human CCN2 (hCCN2), formerly designated human
connective tissue growth factor (hCTGF) [13], is a 349
amino acid polypeptide that was first identified as a prod-
uct of human umbilical vein endothelial cells, and which
is chemotactic and mitogenic for fibroblasts [14]. It is
now known to be one of the seven cysteine-rich secreted
Riser et al: Urinary CCN2 (CTGF) and nephropathy452
proteins that comprise the CCN family (named for its
original members, cry61, CTGF and NOV) [15]. The
CCN proteins are composed of four modules and one
signal peptide [15]. The four modules include an insulin-
like growth factor (IGF) binding domain, a von Wille-
brand factor type C module, a thrombospondin type 1
repeat, and a C-terminal module. However, the function
of each of the modules is not yet clear. Human, mouse,
and rat CCN2 are highly conserved proteins with greater
than 90% homology at the amino acid level [15].
An important emerging role for CCN2 is that of a
prosclerotic mediator. In renal biopsy specimens from
patients with various forms of renal disease, including
crescentic glomerulonephritis, immunoglobulin A (IgA)
nephropathy, focal and segmental glomerulosclerosis,
and diabetic nephropathy, it has been shown that CCN2
gene expression is up-regulated [16]. Our laboratory has
previously demonstrated that cultured mesangial cells
express low levels of CCN2 mRNA and CCN2 protein
[17]. However, exposure of these cells to high glucose
concentrations, mechanical strain, or transforming growth
factor- (TGF-), all causal factors in diabetic nephropa-
thy [18, 19], resulted in increased levels of CCN2 gene
expression and protein secretion [17]. In vivo studies
using the db/db mouse model of type 2 diabetes demon-
strated by quantitative reverse transcription-polymerase
chain reaction (RT-PCR) that CCN2 transcripts were
low in the glomeruli of control mice, whereas this expres-
sion was increased 28-fold early in the course of diabetic
nephropathy at a time when mesangial expansion was
mild and proteinuria was within the control range. Mea-
surements of concomitant CCN2 mRNA in the whole
renal cortex indicated that the primary alteration of
CCN2 renal expression was in the glomeruli [17]. Taken
collectively, these results suggested that CCN2 up-regu-
lation is an important early factor in the pathogenesis
of extracellular matrix (ECM) accumulation that charac-
terizes diabetic and nondiabetic glomerulosclerosis. In
the present study, we have investigated the possibility
that CCN2 is an early urinary prosclerotic factor, the
excretion level of which can be correlated with the devel-
opment of glomerulosclerotic process in diabetic ne-
phropathy. This preliminary report supports the idea
that measurement of urinary CCN2 in diabetic patients
may serve to predict the future development of nephro-
logic complications. Confirmation of this hypothesis will
be determined in a study current ongoing expanded pa-
tient study.
METHODS
Recombinant CCN2 and anti-CCN2 antibodies
Recombinant human CCN2 protein (rhCCN2) was
generated as previously described [17] in a baculoviral
expression system and purified by heparin sepharose af-
finity chromatography. Two anti-CCN2 antibodies, which
we have previously described, were used [17]. For West-
ern blotting, the antibody used was anti-CCN2 poly-
clonal pAb839, originally generated against amino acids
329-343 (CPG DND IFE SLY YRK) and unique to the
CCN2 carboxy terminus. Peptide blocking studies con-
firmed the specificity of pAb839 for CCN2 in immuno-
blotting assays. For enzyme-linked immmunosorbent as-
say (ELISA), the antibody used was polyclonal pIgY3,
produced by immunizing chickens with purified baculo-
virus-derived full-length rhCCN2 protein.
ELISA for urinary CCN2
A modified ELISA was used to quantify CCN2 levels
in urine [17]. In brief, the wells of a microtiter plate were
coated with undiluted urine or rhCCN2 standard (50 L/
well) for 2 hours at room temperature, washed with
phosphate-buffered saline (PBS), and then incubated
with pIgY3 antibody in blocking buffer (1%BSA, 0.05%
Tween 20 in PBS) for 60 minutes. After washing with
PBS, a peroxidase-conjugated rabbit anti-chicken IgG
(Zymed Laboratories, Inc., South San Francisco, CA,
USA) was added. The substrate, TMB-ELISA from Gibco
(Carlsbad, CA, USA) was added and the color intensity
read at 620 nm with a Titertek Multiscan MCC/340 (Flow
Laboratories, McLean, VA, USA).
Western blotting for CCN2
Western analysis for CCN2 protein was carried out as
previously described for cell culture supernatants [17].
Briefly, CCN2 in urine samples was heparin sepharose–
extracted and specimens then boiled in sodium dodecyl
sulfate (SDS) sample buffer under nonreducing or reduc-
ing conditions [17]. The proteins were resolved on 4% to
20% SDS-polyacrylamide gels, transferred to nitrocellu-
lose, and then probed for CCN2 by incubation with anti-
CCN2 antibody. The secondary antibody was an horse-
radish peroxidase (HRP)-conjugated rabbit anti-chicken
IgG. Immunoreactivity was detected with a chemilumi-
nescent system (SuperSignal; Pierce, Rockford, IL, USA).
Animals and induction of experimental diabetes
Insulin-deficient diabetes was induced in male Fischer
rats (150 to 180 g) by a single intravenous injection of
55 mg/kg streptozotocin (STZ) (Sigma Chemical Co., St.
Louis, MO, USA) immediately following dissolution in
acidified saline. An equal volume of buffer was injected
into control animals. To maintain body weight and pre-
vent ketoacidosis, hyperglycemia was partially corrected
(300 to 350 mg/dL) with daily administration of Ilentin II
insulin (Eli Lilly, Indianapolis, IN, USA). All procedures
were carried out with appropriate institutional approval
following the guidelines for the use and care of animals.
Animals were housed in accordance with good practice
guidelines established by AALAC-approved animal care
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facilities of Henry Ford Hospital. Animals were fed stan-
dard Purina rat chow (Ralston Purina Co., St. Louis,
MO, USA) and permitted free access to water.
Patients
Consecutive patients making routine visits to either
the nephrology or the endocrinology clinics of Henry
Ford Hospital were studied. Excluded were patients with
diagnoses other than diabetes. Patients were divided into
two groups. Those with renal insufficiency (serum crea-
tinine 1.8 mg/dL) and/or clinical proteinuria (30
mg/dL protein, by dipstick) were placed the renal disease
group, whereas patients with neither proteinuria nor re-
nal insufficiency were placed in the group without renal
disease. In some patients, only a single protein value was
available, but in those cases the value was from the
same collection as was used for the CCN determination.
During the same period, samples were obtained from
healthy volunteers with no history of diabetes, hyperten-
sion, or renal disease. Consent was obtained after the
nature of the procedure and study was explained. No
patients, who were asked, refused to take part in the
study. For the quantitative study of urinary CCN2, the
mean age was 58.9  16.5 years and 51.8  12.42 years
(SD), respectively, for groups with and without renal
disease. In the group of seven patients with renal disease,
six patients were hypertensive, four required insulin, and
two were being treated with an ACE inhibitor or an
angiotensin receptor blocker. In the group of six patients
without renal disease, three were hypertensive, four re-
quired insulin, and two were being treated with an ACE
inhibitor. For the qualitative study of urinary CCN2,
four patients were studied, all required insulin, two had
renal insufficiency and/or clinical proteinuria, three were
receiving ACE inhibitor therapy, and three were hyper-
tensive. Healthy volunteers had no history of diabetes,
hypertension, or renal disease.
Collection and processing of urine samples
For animal studies, rats were placed in metabolic cages
for a 24-hour adjustment period before duplicate 24-
hour urine samples were obtained. The data from two
consecutive 24-hour collections in each individual animal
were pooled. For human studies, freshly voided urine
was collected from patients during their routine visits to
either the nephrology or the endocrinology clinics of
Henry Ford Hospital. During the same period, samples
were obtained from healthy volunteers with no history
of diabetes, hypertension, or renal disease. Consent was
obtained after the nature of the procedure and study was
explained. All samples were maintained at 4C during
handling (maximum 6 hours for human samples and 2
hours for animal samples) before storage at70C. Sam-
ples were later thawed, centrifuged, and assayed directly,
by ELISA, or following heparin sepharose–extraction
by immunoblotting. Urine creatinine values were deter-
mined with a VITROS 250 analyzer (Johnson and John-
son, Rochester, NY, USA). Albumin levels in rat urine
samples were determined by competitive ELISA using
Nephrat (Exocell, Philadelphia, PA, USA).
Statistical analysis
Ratio estimator methods were used to compare CTGF/
creatinine levels and albumin/creatinine levels in the two
animal groups at each time point. Time points within
a group were compared using ratio estimator methods
taking into account the paired nature of the data. The
data were transformed using a natural log transformation
to account for nonnormality and Hochberg’s method was
used to adjust for multiple comparisons [20]. Statistical
analysis of the CTGF/creatinine levels in the human data
was performed by analysis of variance followed by t tests
for pair-wise comparisons. A natural log transform of
the data was used to correct nonnormality within groups.
The analysis of variance (ANOVA) of Welch [21] and
the variance approximation of Satterthwaite [22] were
used to account for the difference in variance between
groups. The method of Hochberg [20] was used to adjust
for multiple comparisons.
RESULTS
Urinary CCN2 in normal and diabetic rats
To determine if CCN2 was present in urine and the
effect of diabetes, 12 rats were made diabetic by STZ
injection and urine samples collected after 3, 8, 11, 16,
and 32 weeks of diabetes. Urine samples were also col-
lected at these same periods from six age-matched healthy
controls. CCN2 levels were determined by ELISA and
expressed as the ratio of urinary creatinine. We found
that overall concentrations of the cytokine among con-
trols were 6.75  1.1 ng CCN2/mg creatinine as com-
pared to 49.0  11.8 ng CCN2/mg creatinine (SD) in
diabetic animals (mean of all collections). This repre-
sented an average sevenfold increase in CCN2 following
the onset of diabetes. The time course study showed that
urinary CCN2 was present at consistently low levels at
all time points in control animals (Fig. 1). In contrast,
CCN2 amounts were substantially elevated shortly after
the induction of diabetes. The levels in diabetic animals
remained significantly elevated compared to age-matched
controls during the entire study period (Fig. 1). However,
with diabetes, there was a gradual decrease in the amount
of CCN2 excreted with time. That is, the excretion at 32
weeks following diabetes was significantly lower than
that at 3 weeks. The amount of urinary CCN2 in healthy
animals also decreased significantly with time, although
to a lesser degree (Fig. 1).
To determine the relationship between CCN2 and uri-
nary albumin excretion, albumin was measured and also
normalized for creatinine in the same sample. Unlike that
observed for CCN2, albumin levels were consistently low
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Fig. 1. Rat urinary CCN2 and the influence of diabetes. Concentrations
in two consecutive 24-hour urine samples were measured by enzyme-
linked immunosorbent assay (ELISA) and normalized to the amount
of creatinine in the same sample. All CCN2 values (mean log  SE) in
the experimental group (N 12) were significantly different than those
in the control group (N 6) at the corresponding periods (P 0.0001).
Within each group, CCN2 levels decreased significantly over time. *P
0.0006 versus 3 weeks; **P  0.0001 versus 11 weeks; ***P  0.032
versus 8 weeks and 11 weeks.
in both groups until 32 weeks (Fig. 2). At this latter period,
urinary albumin levels rose substantially in the diabetic
group, resulting in significant (P  0.042) differences as
compared to albumin excretion in controls (Fig. 2).
Urinary excretion of CCN2 in control
and diabetic patients
To determine if the increase in CCN2 excretion ob-
served in STZ-diabetic animals reflected changes in hu-
mans with diabetes, we quantified urinary CCN2 excre-
tion in healthy controls, diabetic patients, and diabetic
patients with renal disease. CCN2 levels were determined
to be consistently low among the healthy volunteers (mean,
7.1  3.0 ng/mg creatinine) (SD). Interestingly, how-
ever, in the diabetic patient group without renal disease,
four of six patients demonstrated CCN2 levels equal to
those of healthy volunteers, whereas the other two ex-
creted substantially elevated (average ninefold) amounts
of the protein (Fig. 3). Of the four patients in this group
whose albumin/creatinine ratios were available, all were
normoalbuminuric, including the two patients with high
levels of urinary CCN2. Neither of the two patients with
elevated CCN2 levels was receiving ACE inhibitor ther-
apy. In the group of diabetic patients with renal disease,
five of seven demonstrated significantly elevated CCN2
levels (mean of five, 42.1  13.6 ng/mg creatinine or a
sixfold increase over controls) (Fig. 3). Two of the five
patients with renal disease and high CCN2 levels were
Fig. 2. Urinary CCN2 albumin levels in streptozotocin (STZ)-diabetic
and control rats. Concentrations of albumin were measured following
urine collection as described in Figure 1. The value (mean  SE.) of
albumin in diabetic animals (N  12) was significantly greater at 32
weeks than the corresponding control (N  6) group (P  0.042).
receiving ACE inhibitor therapy, whereas neither of the
two patients with renal disease but low CCN2 values
was receiving such therapy. To compare the three groups,
including all samples, an analysis of variance with the
log transformation of the data was used. The values from
the volunteer group did not differ from the diabetic pa-
tient group without renal disease as a whole (control,
1.90  0.45 SD; patient, 2.56  1.25 SD, P  0.35).
However, there was a significant difference between the
control group and the diabetic patients with renal disease
(control, 1.90  0.45 SD; patient, 3.18  0.99, P  0.01).
To identify the molecular form of CCN2 present and
the stability of CCN2 in urine, a sample was collected
from a healthy volunteer then divided into five aliquots.
Increasing quantities of rhCCN2 were added to four
aliquots, whereas a fifth received diluent only. The ali-
quots were incubated at 37C for 4 hours then frozen at
–70C. Samples were subsequently processed and ana-
lyzed by Western blotting in parallel with rhCCN2 in
buffer alone. The sample with urine alone demonstrated
the presence of CCN2, appearing as a 37/39 kD doublet
(Fig. 4). This molecular form is characteristic of the full-
length CCN2 molcule produced by cells in culture [17].
Preserved integrity of CCN2 was indicated by the ex-
pected progressive increase in amounts of full-length
CCN2 recovered. Notably, only exceedingly high con-
centrations of added CCN2 demonstrated the presence
of a lower-molecular-weight CCN2 fragment, in this case,
equal to the half the full-length molecule (Fig. 4).
Finally, we investigated the possibility that the molecu-
lar form of urinary CCN2 might be altered among dia-
betic patients with established nephropathy. Accordingly,
urine samples from four type 1 diabetic patients with
Riser et al: Urinary CCN2 (CTGF) and nephropathy 455
Fig. 3. Measurement of urinary CCN2 from
patients and healthy volunteers. Urinary CCN2
levels were measured by enzyme-linked im-
munosorbent assay (ELISA). Each bar repre-
sents the determination from an individual pa-
tient sample run in triplicate. The dashed line
indicates the mean value for all healthy volun-
teers.
Fig. 4. Identification of urinary CCN2 protein in a healthy donor and
the stability of added recombinant molecule. Urine was collected from
a healthy donor who demonstrated detectable CCN2 level by enzyme-
linked immunosorbent assay (ELISA). The sample was divided into
five, 25 mL aliquots. Increasing amounts of recombinant human CCN2
(rhCCN2) (25 to 750 ng) were added to four of the aliquots. As a
control, buffer only was added to the fifth aliquot. Immunoblotting was
performed using CCN2-specific antibody.
renal disease and three healthy volunteers were collected.
The CCN2 in urine samples was concentrated by hepa-
rin-sepharose extraction, then analyzed by Western blot-
ting. Immunoreactive CCN2 appeared in three different
molecular forms. A 37/39 kD doublet representing full-
length CCN2 was present in two of four patient samples
(Fig. 5, lanes A and D) and one control sample (Fig. 5,
lane G). Interestingly, a large-molecular-weight band of
approximately 200 kD was present in each patient sample,
but appeared only as a very faint band in a single control
sample (Fig. 5). Also present was a small CCN2 fragment
of approximately 9 to12 kD. This CCN2 fragment ap-
peared in the urine of three of the four diabetic patients
(Fig. 5, lanes A, C, and D), but was absent in all healthy
individuals (Fig. 5, lanes E, F, and G). This smaller moi-
ety is equivalent to the heparin-binding C-terminal quar-
ter fragment of CCN2.
Fig. 5. Immunoblot analysis of urinary CCN2 from healthy volunteers
and diabetic patients. Representative urine samples from four unse-
lected patients (lanes A to D) collected during routine visits and three
healthy volunteers (lanes E to G) were processed and examined for
CCN2 by immunoblotting using CCN2-specific antibody.
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DISCUSSION
This study demonstrates, for the first time, the pres-
ence of the prosclerotic cytokine CCN2 (formerly named
CTGF) in urine. When normalized for urine creatinine,
low levels of CCN2 were present in normal rats. How-
ever, with the establishment of experimental diabetes,
there was a sevenfold elevation in the level of total
CCN2. These levels exceeded controls for the entire
32-week period of observation. However, they declined
slowly and significantly with time after their initial rapid
elevation by week 3. The finding that CCN2 levels in
nondiabetic animals also declined with time suggested
an effect of normal aging. However, the drop was not
entirely independent of diabetes, since the decline ob-
served in diabetic rats was substantially greater than
that among nondiabetic controls. This increase in urinary
CCN2 preceded the time that we previously reported
for the up-regulation of CCN2 message in tissue of db/db
diabetic mice at 31/2 months of disease [17]. However,
earlier examinations of mRNA levels were not per-
formed. Based on the findings presented here, one might
expect renal CCN2 transcript levels in db/db diabetic
mice to be elevated considerably sooner than 31/2 months.
Murphy et al [23] found measurable CCN2 mRNA in
the renal cortex of STZ-diabetic rats 4 months after
surgery when, in this model, mesangial expansion and
proteinuria were present, but did not report on earlier
time periods.
Our initial investigations in human beings, using a lim-
ited patient population, showed that urinary CCN2 levels
were consistently low among healthy volunteers, whereas
the majority of those with diabetes and nephropathy dem-
onstrated on average a sixfold increase in excretion. The
finding that CCN2 levels in two of the patients within
this group were not different from those in the control
group was not unexpected and suggests that in diabetic
nephropathy other factors may affect excretion. One
factor may be the stage of progression. This is supported
by our animal study where there was an early elevation
in urinary CCN2 levels following the onset of diabetes,
with values subsequently decreasing over time and ap-
proaching those of normal control animals after 32
weeks. Another factor that may influence urinary CCN2
excretion is patient medication. There appeared to be
no indication that those receiving ACE inhibitor or an-
giotensin receptor blocker therapy demonstrated re-
duced CCN2 excretion. However, the patient population
was too small to accurately determine an effect. An effect
of such therapeutics on urinary CTGF excretion will be
important in future expanded determinations.
In the patient group with diabetes but with no renal
disease, two of six patients demonstrated marked eleva-
tion in CCN2 excretion (eight- and tenfold over con-
trols). The remaining four patients showed CCN2 levels
within the range of the normal volunteers. Both of the
patients with high CCN2 excretion were normoalbumi-
nuric at the time of assay. Although not yet proven, these
findings support our hypothesis that increased urinary
CCN2 may precede progressive nephropathy. The mean
levels in those diabetic patents with elevated urinary
CCN2, but without nephropathy, were considerably
higher than the mean levels in diabetic patients with
renal disease. This is in agreement with the concept that
in susceptible patients, CCN2 levels are elevated early,
and then fall as the renal disease becomes established.
The possibility that elevated CCN2 may occur in re-
sponse to diabetes, but independent of renal alterations,
cannot be ruled out at this time. However, this seems
unlikely when interpreted in the context of our findings
that in experimental diabetes, alterations in available
renal CCN2 are associated with the early development of
glomerulosclerosis, and CCN2 in vitro stimulates ECM
synthesis by renal cells [24]. Further, we recently deter-
mined by RT-PCR amplification of mRNA from renal
biopsies that patients with type 1 diabetes have glomeru-
lar CCN2 transcripts that are elevated in the presence of
microalbuminuria and overt proteinuria [25]. We found a
positive correlation between glomerular CCN2 mRNA
levels and albuminuria and fractional mesangial area
[25]. Collectively, this supports the idea that the changes
in urinary CCN2 levels observed in the present study
reflect changes in synthesis occurring in the kidney.
In immunoblotting studies, we found that among
healthy volunteers the low urinary CCN2 levels as de-
tected by ELISA produced either a weak doublet band
at 37/39 kD or no detectable band. The larger protein
of this doublet is equivalent in size to the full-length
CCN2 molecule predicted from gene analysis. The
smaller peptide may represent differential N-glycosyla-
tion of CCN2 [17]. The full-length CCN2 forms detected
in normal urine are like those previously reported in
fibroblasts, endothelial, and mesangial cells [14, 17, 26]
and suggests that at least the majority of urinary CCN2
remains intact. In support of this notion, we found that
rhCCN2, when added to normal urine, was recoverable
as full-length molecules. The finding of a large, 200 kD,
immunoreactive species in all urine samples from type 1
diabetic patients was unanticipated. This band was pres-
ent as a weak signal in only one of the healthy volunteers.
The identity of this large molecule is currently unknown,
but most likely represents CTGF complexed to a second
urinary protein. A small molecule equal in size to the
quarter-length fragment of CCN2 was also present in
three samples. Interestingly, this represented three of
the four patients in the study. Ball et al [27] had reported
a similar small fragment in the uterine cavity of pig and
Steffen et al [26] reported a similar fragment in human
and mouse fibroblast cultures. We have previously dem-
onstrated the presence of smaller-molecular-weight
forms of CCN2, equivalent to both the half- and quarter-
length fragments in mesangial cell cultures stimulated
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by TGF- [17]. To date, the biologic function(s) of these
fragments has not been established. It is also unknown
whether these forms arise as the result of proteolysis of
full-length CCN2, or represent components of one larger
molecule to be assembled. Determining whether the uri-
nary quarter-length fragment of CCN2 is characteristic
of diabetic nephropathy is compelling and will require
more detailed investigation.
We did not determine that urinary CCN2 was pro-
duced in the kidney. Its size and charge predict that any
CCN2 present in the circulation would be freely filtered
in the glomerulus. However, we have clearly shown that
the db/db mouse greatly augments renal CCN2 gene
expression by 31/2 months following the onset of diabetes,
thus implying local synthesis [17, 24]. This renal CCN2
expression appears to be concentrated in the glomerulus
since isolated glomeruli demonstrate a 27-fold increase
in transcript levels compared to only a doubling of corti-
cal CCN2 transcripts. Conceivably, the mesangial cell
could be responsible for a large proportion of the CCN2
observed in urine. Also, in our previous study, we re-
ported that mesangial cells constitutively express little
CCN2 mRNA or protein. However, following exposure
to promoters of diabetic nephropathy, including TGF-,
high levels of glucose, or mechanical strain, there is a
marked increase in CCN2 expression. In another model,
at 4 weeks following partial nephrectomy in rats, CCN2
expression was reported in regions of proliferating inter-
stitial stromal fibroblasts and myofibroblasts, whereas
expression was limited to a few interstitial and glomeru-
lar epithelial cells in control organs [28]. Along these
lines, cultured renal fibroblasts have been shown to up-
regulate expression of CCN2 following stimulation by
TGF- or lysophosphatidic acid (LPA) [29]. Further, pa-
tients with various forms of renal disease, including cres-
centic glomerulonephritis, IgA nephropathy, focal and seg-
mental glomerulosclerosis, and diabetic nephropathy, have
been demonstrated to express increased CCN2 mRNA as
compared to that found in control renal tissue [16].
The accumulation of ECM characterizes diabetic ne-
phropathy and involves not only increased synthesis but
also altered turnover. Therefore, the measurement of
matrix molecules as well as proteinase/proteinase inhibi-
tors in the serum [30] or urine [31] have recently been
considered as possible markers of nephropathy. How-
ever, as with microalbuminuria, changes in these markers
may not be significant until relatively late in the progres-
sion of disease [10–12]. Monitoring TGF- in the urine
or serum seems attractive since its up-regulation in the
glomerulus is early and is causal for changes in ECM
accumulation [32–36]. Work along these lines is being
pursued and may prove fruitful [31, 37]. However, the
highly ubiquitous nature of this growth factor and the
existence of multiple circulating forms that contrast with
active local forms present difficulties in the interpretation
of results.
CONCLUSION
Our findings demonstrate unequivocally that CCN2
excretion is abnormal in the urine of diabetic humans
and rats. Furthermore, the molecular forms of CCN2
excreted are altered in diabetes. These findings support
our hypothesis that CCN2 is up-regulated early in dia-
betic patients that are destined for nephropathy, and
then diminishes during the evolution of progressive renal
disease. We contend that the measurement of urinary
CCN2 may allow one to predict and stage patients des-
tined for progressive diabetic glomerulosclerosis and
ESRD. Ultimately, proof of concept will require ex-
panded patient studies, including a longitudinal analysis
beginning prior to the development of microalbumin-
uria. Such a study is underway in our laboratory.
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